Chiltern Joins Association of Clinical Research Organizations Becoming Second European-based ACRO Member

WASHINGTON--(BUSINESS WIRE)-- The Association of Clinical Research Organizations, which represents the CRO industry globally, is pleased to announce that Chiltern, headquartered in Berkshire, United Kingdom, has joined ACRO and that Glenn Kerkhof, Chiltern CEO, will be the company’s representative to the Association.

“We welcome Chiltern into ACRO and look forward to exchanging views and perspectives with Glenn as he represents one of the larger European-based CROs,” said William Sharbaugh, ACRO Chair and COO of PPD.

Established in 1982, Chiltern is a leading global CRO with extensive experience conducting and staffing Phase I to Phase IV clinical trials. The company employs more than 1,400 people within 19 countries.

“ACRO’s membership is expanding internationally just as our focus is increasingly global in scale,” said Doug Peddicord, Ph.D., ACRO Executive Director. “We invite all CROs with global aspirations to demonstrate their commitment to the industry by joining ACRO.”

You may become a fan of ACRO on Facebook and follow us on Twitter @ACROhealth.

About ACRO

The Association of Clinical Research Organizations (ACRO) represents companies whose focus is clinical research. The association provides an active voice for the global CRO industry, which provides specialized services that are integral to the development of drugs, biologics and medical devices. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ approximately 70,000 professionals worldwide and annually conduct more than 9,000 clinical trials involving nearly two million participants in 115 countries. For more information, please visit www.acrohealth.org.



CONTACT:

Association of Clinical Research Organizations
John Lewis, 202-464-2310 (office)
202-285-5726 (mobile)
[email protected]

KEYWORDS:   United Kingdom  United States  Europe  North America  District of Columbia

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Clinical Trials  Pharmaceutical  FDA

MEDIA:

Logo
 Logo

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.